SUBSCRIBE
SUBSCRIBE

C2N Diagnostics

NEWS
Pictured: A funnel of American cash/iStock, ardasa
Healthcare Industry Poised to Profit from New Alzheimer’s Treatments
In addition to massive revenues predicted for their developers, Leqembi—and possibly donanemab, if approved—should bring in substantial dollars to the healthcare industry.
September 5, 2023
 · 
7 min read
 · 
Kate Goodwin
Pictured: Close-up of an arm receiving a blood dra
Drug Development
New Biomarker Tests Aid Quick, Accurate Diagnosis of Alzheimer’s Disease
With new Alzheimer’s drugs receiving—and expected to receive—FDA approval, the market for diagnostic biomarker tests is set to expand.
August 30, 2023
 · 
6 min read
 · 
Claire Jarvis
IN THE PRESS
BioMidwest
C2N Diagnostics Reports High Accuracy of APTUS™-Aβ Blood Test for Detecting Early Alzheimer’s Disease Pathology
December 9, 2019
 · 
5 min read
BioMidwest
C2N Diagnostics to Report Results of APTUS™-Aβ Blood Test for Alzheimer’s Disease Brain Pathology
December 2, 2019
 · 
2 min read
FDA
C2N Diagnostics Receives Breakthrough Device Designation from U.S. FDA for Blood Test to Screen for Alzheimer’s Disease Risk
January 29, 2019
 · 
4 min read
Drug Development
C2N Reports Phase I Study Results Of C2N-8E12 (ABBV-8E12) – Anti-Tau Antibody – In Subjects With Progressive Supranuclear Palsy
December 9, 2016
 · 
4 min read
Drug Development
C2N Completes Phase I Clinical Study Of C2N-8E12 (ABBV-8E12) Among Individuals With Progressive Supranuclear Palsy
October 13, 2016
 · 
3 min read
Drug Development
C2N And AbbVie Announce FDA Orphan Drug Designation Of C2N-8E12 (ABBV-8E12) For The Treatment Of Progressive Supranuclear Palsy
July 17, 2015
 · 
5 min read
Business
AbbVie And C2N Enter Into A Worldwide License Agreement For Alzheimer’s Disease Therapy
March 19, 2015
 · 
3 min read
Load More
JOBS